Designing COVID-19 Vaccine That Partially Mimics Structure Of SARS-CoV-2 Virus Could Increase Its Effectiveness
By HospiMedica International staff writers Posted on 29 Oct 2020 |
Image: A close-up view of the RBD particle vaccine (green) (Photo courtesy of McGill University)
A research team at University at Buffalo (Buffalo, NY, USA) has discovered a technique that could help increase the effectiveness of vaccines against the novel coronavirus, the virus that causes COVID-19.
Amidst active efforts to develop an effective COVID-19 vaccine, the University at Buffalo-led research team believes that one answer might lie in designing vaccines that partially mimic the structure of the virus. One of the proteins on the virus - located on the characteristic COVID spike has a component called the receptor-binding domain, or RBD, which is its “Achilles heel.” Antibodies against this part of the virus have the potential to neutralize the virus. The team hypothesized that by converting the RBD into a nanoparticle (similar in size to the virus itself) instead of letting it remain in its natural form as a small protein, it would generate higher levels of neutralizing antibodies and its ability to generate an immune response would increase.
The team had previously developed a technology that makes it easy to convert small, purified proteins into particles through the use of liposomes, or small nanoparticles formed from naturally-occurring fatty components. In the new study, the researchers included within the liposomes a special lipid called cobalt-porphyrin-phospholipid, or CoPoP. That special lipid enables the RBD protein to rapidly bind to the liposomes, forming more nanoparticles that generate an immune response. The team observed that when the RBD was converted into nanoparticles, it maintained its correct, three-dimensional shape and the particles were stable in incubation conditions similar to those in the human body. When laboratory mice and rabbits were immunized with the RBD particles, high antibody levels were induced. Compared to other materials that are combined with the RBD to enhance the immune response, only the approach with particles containing CoPoP gave strong responses. Other vaccine adjuvant technology does not have the capacity to convert the RBD into particle-form, according to the researchers.
“We think these results provide evidence to the vaccine-development community that the RBD antigen benefits a lot from being in particle format. This could help inform future vaccine design that targets this specific antigen,” said Jonathan F. Lovell, PhD, associate professor in the Department of Biomedical Engineering at UB, the primary investigator on the research.
Related Links:
University at Buffalo
Amidst active efforts to develop an effective COVID-19 vaccine, the University at Buffalo-led research team believes that one answer might lie in designing vaccines that partially mimic the structure of the virus. One of the proteins on the virus - located on the characteristic COVID spike has a component called the receptor-binding domain, or RBD, which is its “Achilles heel.” Antibodies against this part of the virus have the potential to neutralize the virus. The team hypothesized that by converting the RBD into a nanoparticle (similar in size to the virus itself) instead of letting it remain in its natural form as a small protein, it would generate higher levels of neutralizing antibodies and its ability to generate an immune response would increase.
The team had previously developed a technology that makes it easy to convert small, purified proteins into particles through the use of liposomes, or small nanoparticles formed from naturally-occurring fatty components. In the new study, the researchers included within the liposomes a special lipid called cobalt-porphyrin-phospholipid, or CoPoP. That special lipid enables the RBD protein to rapidly bind to the liposomes, forming more nanoparticles that generate an immune response. The team observed that when the RBD was converted into nanoparticles, it maintained its correct, three-dimensional shape and the particles were stable in incubation conditions similar to those in the human body. When laboratory mice and rabbits were immunized with the RBD particles, high antibody levels were induced. Compared to other materials that are combined with the RBD to enhance the immune response, only the approach with particles containing CoPoP gave strong responses. Other vaccine adjuvant technology does not have the capacity to convert the RBD into particle-form, according to the researchers.
“We think these results provide evidence to the vaccine-development community that the RBD antigen benefits a lot from being in particle format. This could help inform future vaccine design that targets this specific antigen,” said Jonathan F. Lovell, PhD, associate professor in the Department of Biomedical Engineering at UB, the primary investigator on the research.
Related Links:
University at Buffalo
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans